Loading...
ORMP logo

Oramed Pharmaceuticals Inc.NasdaqCM:ORMP Voorraadrapport

Marktkapitalisatie US$158.5m
Prijs aandeel
US$4.09
US$6.25
34.6% ondergewaardeerd intrinsieke korting
1Y70.7%
7D0.8%
Portefeuillewaarde
​
Bekijk

Oramed Pharmaceuticals Inc.

NasdaqCM:ORMP Voorraadrapport

Marktkapitalisatie: US$158.5m

Oramed Pharmaceuticals (ORMP) Aandelenoverzicht

Oramed Pharmaceuticals Inc. houdt zich bezig met het onderzoek naar en de ontwikkeling van farmaceutische oplossingen met een technologieplatform voor de orale toediening van therapeutische eiwitten. Meer informatie

Beloningen

De koers-winstverhouding ( 2.5 x) ligt onder de US markt ( 19.1 x)

Dit jaar winstgevend geworden

Risicoanalyse

Hoog niveau van niet-contante inkomsten

Heeft geen zinvolle omzet ( $2M )


ORMP Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Oramed Pharmaceuticals Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Oramed Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoersUS$3.91
52 Week HoogtepuntUS$4.22
52 Week LaagUS$1.98
Bèta1.26
1 maand verandering11.08%
3 maanden verandering14.66%
1 Jaar Verandering70.74%
3 jaar verandering38.65%
5 jaar verandering-61.89%
Verandering sinds IPO2,050.41%

Recent nieuws en updates

Seeking Alpha • Dec 24

Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback

Summary Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group. Validating the Protein Oral Delivery Platform in this subset could unlock broader applications beyond insulin. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Dec 24

Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback

Summary Oramed remains viable after its flagship product failed FDA trials three years ago. Management identified a responsive patient subset—elderly with low BMI and high baseline HbA1c—prompting a new 60-patient trial. Positive results from ORMP's Chinese partner reinforce the potential for this narrower patient group. Validating the Protein Oral Delivery Platform in this subset could unlock broader applications beyond insulin. Read the full article on Seeking Alpha
Analyse-artikel • Nov 21

Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential

Investors appear disappointed with Oramed Pharmaceuticals Inc.'s ( NASDAQ:ORMP ) recent earnings, despite the decent...
Analyse-artikel • Nov 13

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analyse-artikel • May 31

We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analyse-artikel • Aug 24

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analyse-artikel • May 03

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyse-artikel • Dec 22

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Sep 21

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Summary Results from Oramed Pharmaceuticals's first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. Results from the ongoing Cohorts A and B, using Oravax for Covid-19, are going to be read out Q3 and Q4 of 2022 respectively. An oral GLP-1 drug is being developed in the pipeline to treat patients with Type 2 Diabetes. The global Type 2 Diabetes market opportunity could double to $58.7 billion by 2025. Oramed Pharmaceuticals (ORMP) is a great speculative biotech play to look into. The reason why I state that is because it is developing an oral insulin drug, known as ORMD-0801 for the treatment of patients with Type 2 Diabetes. The reason why I think it can provide traders/investors an opportunity is because it is gearing up to report results from its phase 3 study using this drug for this patient population in January of 2023. This will be results from a late-stage study known as ORA-D-013-1. It did present preliminary results from the use of ORMD-0801 for the treatment of patients with non-alcoholic steatohepatitis ((NASH)) about a week ago. However, the primary endpoint was just looking at safety. The secondary endpoint of liver fat reduction at 12 weeks was not revealed. Just that there was a positive trend in favor of ORMD-0801. It remains to be seen if this NASH indication can be moved forward, but regardless the entire future of this biotech hinges on the phase 3 study using ORMD-0801 for the treatment of patients with Type 2 Diabetes. Even then, it does have a backup clinical candidate in the pipeline known as ORMD-0901 which is an oral GLP-1 analog. There are many other biotechs though who are targeting GLP-1, so whether or not this drug eventually shatters the competition remains to be seen. Still, it is nice to see that this biotech it at least working on another drug to target Type 2 diabetes. There is a final opportunity in developing an oral virus like particle ((VLP)) Covid-19 vaccine known as Oravax. Data is supposed to be out in Q3 of 2022 and then again Q4 of 2022. While not guaranteed for success, it is nice to see another shot on goal in the pipeline. However, the broader strategy here is to apply oral vaccine technology towards other indications that would typically require a vaccine. If somewhat successful with Covid-19, then it's possible to explore such other vaccine indications. Oral Insulin For Type 2 Diabetes Might Become A Reality The first program to go over involves the use of ORMD-0801 for the treatment of patients with Type 2 Diabetes. Type 2 Diabetes occurs as when the body is unable to use insulin properly to control sugar in the bloodstream. This is a larger market opportunity for sure. The reason why I state that is because T2D occurs in 95% of people with diabetes. Some symptoms of Type 2 Diabetes are: Blurry vision Fatigue Extreme thirst Frequent urination As I noted before, this is a very large market opportunity. It is expected that the global market opportunity could double to $58.7 billion by 2025. This is a very good opportunity for Oramed Pharma. In order for Oramed to eventually obtain FDA approval for ORMD-0801 for the treatment of patients with T2D, it has to succeed in one or both of the two ongoing phase 3 studies it has. The first phase 3 study which is currently ongoing is known as ORA-D-013-1. The goal for this trial was to enroll at least 675 patients, but happy to say that they were able to go over targeted enrollment to 710 patients. The primary endpoint of this study is improvement of glycemic control as assessed by A1c over a 26 week period. The secondary endpoint of this late-stage study is a change from baseline in fasting plasma glucose at 26 weeks. As far as a catalyst goes for this program, it is expected that topline results from the phase 3 ORA-D-013-1 study using ORMD-0801 for the treatment of patients with T2D, will be released by January of 2023. First and foremost, the biotech must meet the primary endpoint to succeed for this particular study. Of course, it may also have to do well in the 2nd phase 3 trial I will talk about below. However, should the drug do well in both studies and receive FDA approval, then it will have a few competitive advantages. One competitive advantage being that the drug is given orally instead of as an injection which is a huge improvement to quality of life. It just makes sense, patients would much rather take a drug orally instead of being injected. Secondly, the fact that it is given orally may give an advantage in terms of efficacy. That's because the drug starts to work even before reaching the patient's bloodstream. Lastly, the use of ORMD-0801 for T2D may have an advantage in terms of safety risks. Injectable insulin currently available on the market may cause weight gain and hypoglycemia (lower blood sugar range away from normal). Hopefully Oramed Pharma is successful, because it holds the potential to have the first FDA approved oral insulin drug. It would be huge, because the company already sees that an oral insulin drug would do well from a survey that was done. Such an IQVIA market survey showed that about 76% of physicians would likely prescribe oral insulin instead of injections. In order to really assess whether or not ORMD-0801 is capable of helping patients with T2D, it has an ongoing second phase 3 study in which it is advancing, known as ORA-D-013-2. This trial is expected to enroll up to a total of 450 Type 2 Diabetes patients. These are patients who don't receive an adequate glycemic control by diet only or diet and metformin monotherapy. This late-stage study is a double-blind trial that intends to randomize patients 1:1 into two specific cohorts: One cohort of patients receiving 8 mg ORMD-0801 at night Another cohort of patients receiving once placebo drug at night The primary endpoint here is no different than the primary endpoint for the first phase 3 ORA-D-013-1 study noted above. That is, the efficacy of ORMD-0801 will be compared to placebo in terms of improving glycemic control as assessed by A1c over a 26 week treatment period. The secondary endpoint will be the comparing of ORMD-0801 to placebo in maintaining glycemic control over a 52-week treatment period. I will state that this program could be a bit of a wait. The main topline data in January of 2023 will be crucial of course to see if ORMD-0801 is successful in treating patients with T2D. The problem is that this second phase 3 study will take a big longer. Looking at clinicaltrials site the estimated primary completion date for it is not until at least April of 2023. This means that data from this particular study may not be available until the 2nd half of 2023. Additional Shots On Goal As I indicated above, Oramed is also exploring the use of oral drug ORMD-0801 for the treatment of patients with NASH. Oramed did report preliminary results from the phase 2 study. However, I believe that its future with respect to this indication remains to be seen. The reason why I state that is because of course the safety was reported to be good, the problem is that there was no mention of what the actual percentage of liver fat reduction was. Measurements such as MRI PDFF(%) by MRI, steatosis and fibrosis measured by FibroScan, lipids and HbA1c all showed clinically meaningful trends in favor of ORMD-0801. To be fair, the secondary endpoint was made to assess efficacy in reducing liver fat content in patients with NASH and T2D in a non-statistically significant manner. I believe there is more proof of concept to be done here, therefore, if it does advance forward it would be a great bonus for the pipeline. I would have liked to at least seen some numbers over the 12-week period. While Oramed does have the two ongoing phase 3 studies using ORMD-0801 for the treatment of patients with Type 2 Diabetes, it is not leaving this drug as the only chance of moving a candidate forward for this indication. Having said that, it is pushing forward with a GLP-1 analog for Type 2 Diabetes. There, however, are two specific issues to be aware of though. The first issue being that this drug, known as ORMD-0901, is only being tested in a phase 1 for starters. Secondly, there are a host of competitors who are also developing their very own oral GLP-1 drug. I just wrote an article on Pfizer (PFE) discussing that the big pharma is gearing towards presenting data for its own oral small molecule GLP-1 drug for diabetes. The main premise is that it intends to hold an analyst and investor webcast presentation of oral GLP-1 data at the European Association for the Study of Diabetes (EASD) 2022. This data is going to presented on Wednesday, September 21, 2022 at 4:30 p.m. EDT. There are many other companies with GLP-1 agonists who currently have a portion of the market. Such companies are Novo Nordisk (NVO), Eli Lilly (LLY), AstraZeneca (AZN) and Sanofi (SNY).
Seeking Alpha • Sep 09

Oramed to hand Korean rights for insulin capsule

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a company focused on treatments for diabetes, announced a non-binding agreement with Medicox Co., Ltd. granting the latter exclusive right and license to seek regulatory nod and distribute ORMP’s oral insulin capsule ORMD-0801 in South Korea. The non-binding memorandum of agreement is only for discussion purposes and forms the basis for a definitive distribution license agreement, ORMP said in a regulatory filing Thursday. The 10-year deal includes a transfer price per capsule, milestone, and royalty payments. ORMP has also received a $2M non-refundable payment from Medicox in connection with an undertaking not to grant distribution and license rights to ORMD-0801 in the Republic of Korea until Dec. 15, 2022. The company expects an early 2023 topline data readout for ORMD-0801 from an ongoing Phase 3 trial in type 2 diabetes ahead of a potential submission of a marketing application to the FDA in 2024.
Seeking Alpha • Jul 07

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Oramed Pharmaceuticals (NASDAQ:ORMP), a clinical-stage pharma focused on diabetes and liver diseases, announced on Thursday that despite the challenges in enrollment, the company plans to share data from its Phase 1 trial for oral COVID-19 shot Oravax in 3Q 2022. Issuing a letter to shareholders, Oramed (ORMP) Chief Executive Nadav Kidron noted that the company introduced an additional clinical site amid slower than anticipated enrollment. Oramed (ORMP) has completed the enrollment and dosing in Cohort A with no safety issues so far. While topline data for Cohort A are expected in 3Q, plans are underway to achieve the enrollment target for the Cohort B within this quarter, with data anticipated in 4Q 2022. Recording $169M in cash and Investments as of March 31, Oramed (ORMP) said its cash runway would be adequate to complete the pivotal Phase 3 trials for ORMD-0801 towards a potential FDA approval of the oral insulin candidate. In December, Oramed (ORMP) announced that its subsidiary, Oravax Medical signed an agreement with a Vietnam-based company to sell its oral COVID-19 vaccine in Southeast Asia.
Analyse-artikel • Jun 12

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Apr 14

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity. This is a $15bn market, and there is very little competition.
Analyse-artikel • Feb 23

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Dec 23

Oramed And The Hurdles Of Developing Oral Insulin

Oramed is a leading developer of an oral formulation of human insulin. It uses a permeability enhancer to enable intestinal absorption. A recent cash raise caused the stock to fall drastically.
Analyse-artikel • Nov 02

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 04

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Giant pharma Merck's co-developed oral coronavirus drug with Ridgeback Biotherapeutics has raised interest in non-injected vaccine alternatives. The space was already occupied by Oramed, a clinical-stage biotech, whose oral vaccine is based on its POD technique, together with India's Premas Biotech COVID technology. This is a huge market, but also a highly competitive one due to the sheer number of biotechs involved, but the Israeli company can use previous experience in diabetes and NASH. Still, the fact that its shares have been adversely impacted after Merck's update shows that investors suffered from acidity when digesting the news. I remain bullish on this diversified stock, with market action also showing that its shares have been less battered than for established COVID biotechs.
Analyse-artikel • Aug 24

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

We have been pretty impressed with the performance at Oramed Pharmaceuticals Inc. ( NASDAQ:ORMP ) recently and CEO...
Analyse-artikel • Jul 21

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, Oramed...

Rendement voor aandeelhouders

ORMPUS PharmaceuticalsUS Markt
7D0.8%-1.9%2.1%
1Y70.7%33.3%30.6%

Rendement versus industrie: ORMP overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 33.3 % opleverde.

Rendement versus markt: ORMP overtrof de US markt, die het afgelopen jaar een rendement opleverde van 30.6 %.

Prijsvolatiliteit

Is ORMP's price volatile compared to industry and market?
ORMP volatility
ORMP Average Weekly Movement6.8%
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stabiele aandelenkoers: ORMP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van ORMP is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2002n/aNadav Kidronoramed.com

Oramed Pharmaceuticals Inc. houdt zich bezig met het onderzoek naar en de ontwikkeling van farmaceutische oplossingen met een technologieplatform voor de orale toediening van therapeutische eiwitten. Het ontwikkelt ORMD-0801, een orale insulinecapsule, die zich in fase III van het klinisch onderzoek bevindt voor de behandeling van mensen met diabetes. Het bedrijf heeft licentieovereenkomsten met Oravax Medical Inc. voor de commercialisering van orale vaccins voor COVID-19.

Oramed Pharmaceuticals Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Oramed Pharmaceuticals zich tot de beurswaarde?
ORMP fundamentele statistieken
MarktkapitalisatieUS$158.55m
Inkomsten(TTM)US$63.24m
Inkomsten(TTM)US$2.00m
2.5x
Koers/Winstverhouding
79.1x
P/S-verhouding

Is ORMP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ORMP resultatenrekening (TTM)
InkomstenUS$2.00m
Kosten van inkomstenUS$1.99m
BrutowinstUS$13.00k
Overige uitgaven-US$63.23m
InkomstenUS$63.24m

Laatst gerapporteerde inkomsten

Dec 31, 2025

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)1.56
Brutomarge0.65%
Nettowinstmarge3,162.10%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde ORMP op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

6.4%
Huidig dividendrendement
n/a
Uitbetalingsratio

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/07 13:21
Aandelenkoers aan het einde van de dag2026/05/07 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Oramed Pharmaceuticals Inc. wordt gevolgd door 4 analisten. 0 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Andrew D'SilvaB. Riley Securities, Inc.
Edward NashCanaccord Genuity
Robert LeBoyerLadenburg Thalmann & Company